NCT04952610 - Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Paroxysmal Supraventricular Tachycardia

Interventions

DRUG

Etripamil NS 70 mg

Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.

DEVICE

Aptar Pharma Nasal Spray Bidose System

Aptar Pharma Nasal Spray Bidose System will be supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Trial Locations (23)

10065

Site # 0114, New York

19067

Site # 0105, Yardley

21801

Site # 1007, Salisbury

30309

Site # 0102, Atlanta

31201

Site # 0137, Macon

44710

Site # 1024, Canton

46845

Site # 0149, Fort Wayne

48912

Site # 0166, Lansing

50266

Site # 1025, West Des Moines

57701

Site # 0122, Rapid City

72205

Site # 0160, Little Rock

78723

Site # 1047, Austin

83814

Site # 1115, Coeur d'Alene

91307

Site # 1083, West Hills

92083

Site # 1023, Vista

97330

Site # 1123, Corvallis

43606-

Site # 0110, Toledo

V8T 1Z4

Site # 0213, Victoria

B3H 3A7

Site # 0210, Halifax

L1J 2K1

Site # 2006, Oshawa

M5B 1W8

Site # 0204, Toronto

H1T 1C8

Site # 0203, Montreal

H2X 0A9

Site # 0205, Montreal